Background: Inhibitors of histone deacetylases (HDACis) reactivate HIV replication in in vitro models of HIV latency. However, the recent study by Bullen et al. has underscored the difficulty to reactivate HIV-1 latency in primary resting memory CD4 T cells isolated from aviremic long-term treated HIV-1 infected patients (Bullen et al., Nature Medicine 2014). We hypothesized that mimicking the modalities of administration of HDACis in patients in vivo, and in particular, the continuous exposure of primary resting memory CD4 T cells to HDACis in culture would result in efficient reactivation of HIV-1 replication.
Methods: Resting memory CD4 T cells were isolated from 10 aviremic (<20 HIV-1 RNA copies/mL) long-term treated (>2 years) HIV-1 infected subjects and cultured either in the presence of CD3/CD28 (positive control) or continuous exposure to clinically relevant concentrations of HDACis i.e. SAHA, romidepsin, belinostat, panobinostat and givinostat throughout the culture period of 14 days. HIV-1 RNA and p24 protein were measured at the end of the culture period using validated diagnostic tests.
Results: Using the modified VOA, all the HDACis tested (SAHA, romidepsin, panobinostat, belinostat and givinostat) induced reactivation of HIV-1 replication in primary resting memory CD4 T cells isolated from aviremic long-term treated HIV-1 infected patients as indicated by the high levels of HIV RNA and p24 production measured in culture supernatants. Of note, HIV-1 reactivated in the cell cultures was also infectious as demonstrated by the transmission of HIV-1 infection in vitro to CD8-depleted blood mononuclear cells from healthy subjects. Interestingly, givinostat was more potent than the other HDACis in reversing HIV-1 latency in vitro on the basis of the percentage of patients reactivating HIV and the proportion of HIV positive wells. Finally, the combined treatment of anti-CD3/anti-CD28 MAbs plus givinostat did not result in a significant increase of HIV-1 replication, suggesting that both HDACis and TCR signals may target similar populations of latently HIV-1 infected CD4 T cells.
Conclusions: These results support further investigation and development of HDACis in the armamentarium of the therapeutic agents to achieve HIV functional cure.